Retrospective Trial on Cetuximab Plus Radiotherapy in Elderly Patients with Head and Neck Squamous Cell Cancer.

As reported in the updated MACH-NC meta-analysis, age and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) appeared as the only significant factors influencing CRT efficacy; in fact elderly patients showed a significant shorter Overall Survival (OS) ( p = 0.03) and a negative trend, although non-significant, in Event-Free Survival (EFS) ( p = 0.06) [ 14 ] if compared with younger patients (<65 years old).

also in 1,555 other papers

Median OS was 58 months, with a slightly non-significant positive trend in OS for patients who were non-smokers and those who did not develop G3–4 AEs ( p = 0.786 and 0.799, respectively).

also in 39 other papers

No significant benefit in survival was found between smokers and non-smokers ( p = 0.916) ( Figure 2 A), although with a positive trend in non-smokers with a delta of 6 months.

also in 4,297 other papers